publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
protect
arm
reninangiotensin
system
ra
http
dx
reninangiotensin
system
ra
long
recogn
import
player
pathogenesi
sever
lung
diseas
includ
pulmonari
arteri
hypertens
pah
pulmonari
fibrosi
pf
chronic
obstruct
pulmonari
diseas
copd
acut
respiratori
distress
syndrom
ard
evid
stem
follow
observ
pah
pf
associ
higher
circul
level
angiotensin
ii
ang
ii
b
increas
concentr
angiotensinogen
precursor
ang
ii
peptid
angiotensinconvert
enzym
ace
major
gener
ang
ii
observ
lung
fibrot
pulmonari
hypertens
subject
c
patient
carri
ace
iddd
genotyp
confer
increas
ace
level
suscept
copd
ard
human
lung
fibroblast
obtain
patient
pf
normal
lung
gener
ang
ii
suggest
caus
role
peptid
diseas
pathogenesi
e
ang
ii
induc
apoptosi
alveolar
epitheli
cell
key
initi
factor
lung
fibrogenesi
f
ang
ii
potent
pulmonari
vasoconstrictor
mitogen
properti
produc
migratori
hypertroph
prolif
effect
lung
smooth
muscl
caus
pah
g
ang
ii
mediat
oxid
stress
cytokin
signal
factor
contribut
pathophysiolog
lung
diseas
h
pharmacolog
blockad
ra
use
ace
inhibitor
acei
angiotensin
receptor
blocker
arb
offer
protect
anim
model
copd
pah
lung
fibrosi
collect
find
indic
activ
involv
ra
lung
diseas
howev
clinic
studi
acei
arb
yield
mix
result
fail
reach
consensu
opinion
use
agent
treat
pulmonari
disord
discoveri
sever
new
member
led
emerg
new
arm
ra
forc
reevalu
role
hormon
system
pulmonari
physiolog
pathobiolog
new
compon
includ
monocarboxypeptidas
angiotensinconvert
enzym
vasoact
peptid
angiotensin
ang
g
proteincoupl
receptor
ma
togeth
form
protect
arm
ma
axi
ra
axi
counteract
vasoconstrict
prolif
inflammatori
fibrot
action
ang
ii
sever
target
organ
includ
lung
object
chapter
summar
import
ma
axi
lung
diseas
ii
explor
novel
strategi
upregul
axi
hold
great
potenti
clinic
develop
treatment
pulmonari
disord
classic
ra
compris
cascad
proteolyt
enzym
peptid
locat
primarili
within
circulatori
system
howev
addit
circul
ra
tissuespecif
ra
identifi
sever
organ
includ
heart
kidney
lung
biochem
molecular
studi
reveal
necessari
compon
requir
activ
biosynthesi
ang
ii
name
renin
angiotensinogen
ace
present
within
lung
tissu
furthermor
express
r
r
mrna
protein
level
detect
pulmonari
system
sinc
r
gene
express
abund
r
adult
lung
receptor
mediat
biolog
effect
ang
ii
intrapulmonari
aceang
iiat
r
axi
shown
promot
vasoconstrict
smooth
muscl
cell
prolifer
fibrosi
along
induct
oxid
stress
inflamm
thu
axi
form
vasodeleteri
arm
ra
hand
identif
ma
receptor
within
lung
parenchym
cell
lent
credenc
exist
vasoprotect
arm
ra
believ
imbal
vasodeleteri
vasoprotect
axe
ra
play
crucial
role
pathophysiolog
lung
diseas
zincdepend
metalloproteinas
wide
express
pulmonari
endothelium
type
ii
alveolar
epitheli
smooth
muscl
cell
lung
primari
physiolog
function
metabol
ang
ii
ang
biolog
activ
heptapeptid
bind
ma
receptor
exert
vasodilatori
antiprolif
antifibrot
action
pulmonari
system
becom
increasingli
evid
downregul
ma
axi
contribut
develop
progress
lung
diseas
import
pulmonari
physiolog
appreci
enzym
identifi
function
receptor
sar
coronaviru
sarscov
caus
agent
sever
acquir
respiratori
syndrom
sar
vivo
experiment
studi
reveal
lung
express
markedli
decreas
upon
sarscov
infect
consequ
lead
respiratori
failur
death
protect
role
lung
injuri
underscor
studi
carri
anim
knockout
mice
display
enhanc
vascular
permeabl
increas
lung
edema
neutrophil
accumul
worsen
pulmonari
function
experiment
model
ard
respect
fibrot
lung
diseas
li
et
al
first
demonstr
sever
downregul
catalyt
activ
lung
anim
well
patient
pf
also
inhibitionsilenc
pulmonari
rodent
associ
excess
lung
collagen
accumul
suggest
decreas
level
play
causal
role
lung
fibrogenesi
consist
interpret
mice
defici
gene
suscept
bleomycininduc
injuri
exhibit
excess
deposit
extracellular
matrix
protein
lung
compar
wildtyp
anim
grow
bodi
studi
focus
relev
ma
axi
pah
pah
fatal
lung
diseas
associ
increas
blood
pressur
pulmonari
arteri
decreas
express
enzymat
activ
observ
anim
model
pah
pulmonari
hypertens
patient
along
substanti
increas
circul
ang
ii
level
thu
evid
restor
balanc
vasodeleteri
vasoprotect
axe
ra
could
therapeut
benefici
attenu
diseas
pathogenesi
ard
sever
form
acut
lung
injuri
trigger
sepsi
gastric
juic
aspir
pathogen
infect
sarscov
avian
influenza
viru
experiment
model
ard
treatment
wildtyp
mice
knockout
mutant
catalyt
activ
recombin
protein
rescu
lung
failur
likewis
administr
ang
confer
benefici
effect
acut
lung
injuri
effect
abolish
block
ma
receptor
regard
pah
enzymat
activ
offer
dual
benefici
effect
one
hand
decreas
level
ang
ii
significantli
elev
pah
increas
concentr
vasoprotect
heptapeptid
ang
first
demonstr
pulmonari
overexpress
attenu
monocrotalin
mct
induc
pah
associ
pathophysiolog
similarli
genet
overexpress
ang
render
benefici
effect
diseas
interestingli
coadministr
ma
antagonist
abolish
cardiopulmonari
protect
offer
ang
suggest
involv
masmedi
signal
pathway
separ
set
experi
kleinsass
et
al
demonstr
administr
recombin
human
protein
decreas
hypoxiainduc
pulmonari
vasoconstrict
clinic
front
observ
serum
activ
significantli
reduc
patient
pah
appar
elev
circul
level
pulmonari
hypertens
patient
could
yield
benefici
result
pf
debilit
diseas
mark
scar
lung
treatment
knockout
anim
attenu
bleomycininduc
pf
improv
lung
function
furthermor
studi
group
shown
pulmonari
overexpress
either
ang
lentiviralmedi
gene
transfer
prevent
lung
fibrosi
bleomycin
model
one
hallmark
pf
loss
alveolar
epitheli
cell
aec
mechanist
studi
carri
cultur
aec
reveal
mediat
cell
surviv
balanc
proapoptot
ang
ii
antiapoptot
metabol
product
ang
evidenc
fact
silenc
gene
aec
pharmacolog
inhibit
result
increas
ang
ii
decreas
ang
level
associ
apoptot
cell
death
contrari
treatment
aec
ang
attenu
ang
ii
bleomycininduc
apoptosi
cell
surviv
effect
ang
mediat
inhibit
caspas
caspas
downregul
jun
ntermin
kinas
jnk
pathway
also
ang
mediat
effect
revers
block
ma
receptor
antisens
nucleotid
ma
mrna
taken
togeth
find
implic
potent
antifibrot
role
ang
ma
axi
pf
administr
shown
exert
promis
effect
varieti
diseas
model
patholog
elev
ang
ii
level
dysregul
ra
experiment
find
provid
compel
evid
initi
clinic
trial
regard
glaxosmithklin
current
evalu
effect
formerli
solubl
form
multicent
phase
ii
clinic
trial
treatment
acut
lung
injuri
previou
phase
trial
establish
administr
singl
multipl
dose
well
toler
healthi
human
seriou
advers
event
doselimit
toxic
furthermor
separ
clinic
studi
efficaci
assess
treatment
pah
clinicaltrialsgov
although
clinic
trial
current
way
use
protein
therapi
face
sever
challeng
among
cost
manufactur
recombin
protein
stabil
repetit
intraven
dose
patient
complianc
pose
major
obstacl
realiz
full
therapeut
potenti
therapi
ideal
approach
overcom
aforement
limit
recombin
protein
therapi
would
identifi
small
synthet
molecul
favor
activ
endogen
use
structurebas
drug
design
identifi
synthet
enhanc
resorcinolnaphthalein
dimethylamino
ethyl
amino
hydroxymethyl
sulfonyl
oxi
xnt
diminazen
acetur
dize
silico
dock
studi
reveal
bind
small
molecul
novel
pocket
hingebend
region
protein
stabil
enzym
open
conform
import
open
conform
favorsacceler
enzym
activ
among
three
compound
dize
found
potent
follow
xnt
final
resorcinolnaphthalein
pharmacolog
activ
found
effect
attenu
lung
injuri
addit
xnt
exhibit
strong
antithrombot
action
along
decreas
platelet
attach
wherea
dize
therapi
associ
enhanc
endotheli
progenitor
cell
epc
function
pulmonari
hypertens
anim
factor
could
potenti
cardiopulmonari
benefici
effect
agent
howev
critic
issu
imped
success
translat
activ
clinic
xnt
undesir
pharmacokinet
profil
poorli
solubl
water
requir
acid
ph
solubil
make
unsuit
drug
candid
regard
dize
associ
toxic
side
effect
chronic
treatment
dize
shown
harm
liver
kidney
brain
could
potenti
result
lifethreaten
situat
fact
preslaught
withdraw
period
day
recommend
dize
treat
anim
intend
human
consumpt
besid
dize
found
mutagen
teratogen
nonetheless
xnt
dize
could
serv
lead
compound
requir
structur
modif
make
safe
druggabl
evid
ang
hold
promis
treatment
lung
diseas
howev
use
ang
therapeut
agent
limit
short
halflif
vivo
also
peptid
natur
ang
rapidli
degrad
gastrointestin
tract
given
oral
overcom
issu
formul
ang
extend
halflif
improv
oral
bioavail
current
develop
ang
complex
betacyclodextrin
ang
enabl
effect
oral
administr
signific
increas
plasma
ang
level
addit
klusken
cowork
synthes
cyclic
analog
ang
thioetherbridg
ang
exhibit
better
vivo
pharmacokinet
profil
altern
liposom
deliveri
system
repres
effect
method
administ
ang
administr
liposom
contain
ang
also
found
increas
halflif
heptapeptid
importantli
modifi
form
ang
pharmacolog
activ
test
experiment
model
worth
note
synthet
analog
ang
tarix
pharmaceut
current
clinic
trial
treatment
pah
could
also
promis
candid
pf
therapi
given
stimul
ma
receptor
protect
would
reason
evalu
effect
ma
agonist
pulmonari
therapeut
ave
first
nonpeptid
agonist
ma
receptor
shown
promot
benefici
effect
sever
cardiovascular
diseas
import
aspect
compound
oral
activ
mimic
effect
ang
sever
organ
bind
ma
receptor
recent
two
novel
peptid
cgen
cgen
high
specif
ma
receptor
discov
ma
agonist
potenti
treat
pulmonari
diseas
oral
rout
wide
accept
mean
drug
administr
oral
deliveri
therapeut
protein
like
ang
feasibl
sinc
easili
degrad
gastrointestin
tract
howev
develop
lowcost
oral
deliveri
system
administ
ang
use
transplastom
technolog
use
transplastom
technolog
allow
chloroplast
gener
high
level
therapeut
protein
within
plant
leav
sinc
chloroplast
express
ang
enabl
bioencapsul
therapeut
protein
within
plant
cell
protect
gastric
enzymat
degrad
upon
oral
deliveri
observ
oral
feed
rat
bioencapsul
ang
prevent
develop
mctinduc
ph
associ
improv
right
heart
function
possibl
produc
bulk
quantiti
therapeut
activ
ang
use
transplastom
technolog
hold
great
potenti
clinic
develop
oral
deliveri
system
reduc
number
impair
function
circulatingresid
stem
cell
associ
poor
cardiopulmonari
outcom
patient
experiment
model
lung
diseas
regard
exogen
administr
stem
cell
endotheli
progenitor
cell
bone
marrowor
adiposederiv
mesenchym
stromal
cell
msc
umbil
cord
blood
cell
could
offer
protect
howev
cellbas
therapi
present
number
uniqu
challeng
effect
employ
clinic
set
hostil
environ
character
inflamm
high
oxid
stress
within
diseas
lung
could
threaten
surviv
impair
home
inject
stemprogenitor
cell
genet
modif
cell
overexpress
ang
could
improv
surviv
enhanc
potenti
effect
repair
lung
injuri
fact
shown
prime
endotheli
progenitor
cell
enhanc
function
also
increas
therapeut
efficaci
render
protect
stroke
conclus
dysregul
pulmonari
angiotensin
system
contribut
pathogenesi
progress
lung
diseas
discoveri
protect
ma
axi
provid
novel
promis
target
diseas
treatment
classic
approach
use
acei
arb
innov
pharmaceut
strategi
effect
activ
benefici
ma
axi
hold
great
promis
treat
pulmonari
patholog
